Published in J Urol on May 01, 2008
The incidence of prostate cancer and urothelial cancer in the prostate in cystoprostatectomy specimens in a tertiary care Canadian centre. Can Urol Assoc J (2013) 1.41
Sexual dysfunction after cystectomy and urinary diversion. Nat Rev Urol (2014) 0.81
Commentary on clinical outcomes of sexuality preserving cystectomy and neobladder. J Urol (2008) 0.75
Patients with penile carcinoma benefit from immediate resection of clinically occult lymph node metastases. J Urol (2005) 2.31
How to avoid false-negative dynamic sentinel node procedures in penile carcinoma. J Urol (2004) 2.29
Etiology of squamous cell carcinoma of the penis. Scand J Urol Nephrol Suppl (2000) 2.23
Penile cancer: epidemiology, pathogenesis and prevention. World J Urol (2008) 2.14
The safety and efficacy of sunitinib before planned nephrectomy in metastatic clear cell renal cancer. Ann Oncol (2011) 1.73
Penis conserving treatment for T1 and T2 penile carcinoma: clinical implications of a local recurrence. J Urol (2006) 1.67
Critical appraisal of the PADUA classification and assessment of the R.E.N.A.L. nephrometry score in patients undergoing partial nephrectomy. J Urol (2011) 1.64
Sequential treatment for recurrent localized prostate cancer. J Surg Oncol (2008) 1.45
[Incidence and treatment of prostatic carcinoma in the region of the Comprehensive Cancer Center Amsterdam, 1989-1994]. Ned Tijdschr Geneeskd (1996) 1.40
[Internal radiotherapy in prostatic carcinoma; disappointing long-term results of retropubic Iodine-125 implantation]. Ned Tijdschr Geneeskd (1996) 1.38
[Less mutilating treatment of penile carcinoma]. Ned Tijdschr Geneeskd (2005) 1.35
Upper urinary tract cancer: location is correlated with prognosis. Eur Urol (2005) 1.24
A trial of consent procedures for future research with clinically derived biological samples. Br J Cancer (2009) 1.22
Metastasectomy in renal cell carcinoma: A multicenter retrospective analysis. Eur Urol (1999) 1.22
EAU Guidelines on Penile Cancer. Eur Urol (2004) 1.19
Clinical outcomes after sexuality preserving cystectomy and neobladder (prostate sparing cystectomy) in 44 patients. J Urol (2005) 1.18
Sarcomatoid squamous cell carcinoma of the penis: a clinical and pathological study of 5 cases. J Urol (2004) 1.16
Morbidity of dynamic sentinel node biopsy in penile carcinoma. J Urol (2005) 1.15
Symptomatic brain metastases from small-cell carcinoma of the urinary bladder: The Netherlands Cancer Institute experience and literature review. Ann Oncol (2010) 1.12
Phase II study of intermittent continuous infusion of low-dose recombinant interleukin-2 in advanced melanoma and renal cell cancer. Ann Oncol (1994) 1.10
[Iodine-125 implantation in localized cancer of the prostate; too early for rejoicing]. Ned Tijdschr Geneeskd (1998) 1.07
[The course of prostatic carcinoma]. Ned Tijdschr Geneeskd (1995) 1.07
Epidemiology of human papillomavirus infection. Scand J Urol Nephrol Suppl (2000) 1.01
EAU guidelines on penile cancer. Eur Urol (2002) 0.99
The role of initial immunotherapy as selection for nephrectomy in patients with metastatic renal cell carcinoma and the primary tumor in situ. Eur Urol (2002) 0.99
Intraoperative radioguidance with a portable gamma camera: a novel technique for laparoscopic sentinel node localisation in urological malignancies. Eur J Nucl Med Mol Imaging (2009) 0.98
Detection of occult metastasis in squamous cell carcinoma of the penis using a dynamic sentinel node procedure. J Urol (2000) 0.98
Reactivity to human papillomavirus type 16 L1 virus-like particles in sera from patients with genital cancer and patients with carcinomas at five different extragenital sites. Br J Cancer (2003) 0.95
Sexuality preserving cystectomy and neobladder: initial results. J Urol (2001) 0.95
Brachytherapy after external beam radiotherapy and limited surgery preserves bladders for patients with solitary pT1-pT3 bladder tumors. Ann Oncol (2012) 0.94
Diagnosis and clinical presentation of premalignant lesions of the penis. Scand J Urol Nephrol Suppl (2000) 0.93
Muscle-invasive bladder cancer treated with external beam radiation: influence of total dose, overall treatment time, and treatment interruption on local control. Int J Radiat Oncol Biol Phys (1998) 0.93
Laser therapy for carcinoma in situ of the penis. J Urol (2001) 0.92
Survival after bladder-preservation with brachytherapy versus radical cystectomy; a single institution experience. Eur Urol (2005) 0.91
The place of radiation therapy as definitive treatment of bladder cancer. Int J Urol (1995) 0.89
Dynamic sentinel node biopsy for penile cancer: reliability of a staging technique. J Urol (2002) 0.89
Response to induction chemotherapy and surgery in non-organ confined bladder cancer: a single institution experience. Eur J Surg Oncol (2013) 0.88
Local recurrence after cystectomy and survival of patients with bladder cancer: a population based study in greater amsterdam. J Urol (2005) 0.87
A comparison of physical examination and imaging in determining the extent of primary penile carcinoma. BJU Int (2003) 0.86
Apoptosis, proliferation and p53, cyclin D1, and retinoblastoma gene expression in relation to radiation response in transitional cell carcinoma of the bladder. Int J Radiat Oncol Biol Phys (2001) 0.86
Pseudomyxoma peritonei and the urinary tract: involvement and treatment related complications. J Surg Oncol (2006) 0.86
Standard lymph node dissection for bladder cancer: significant variability in the number of reported lymph nodes. J Urol (2011) 0.86
Neoadjuvant methotrexate, vinblastine, doxorubicin and cisplatin for histologically proven lymph node positive bladder cancer. J Urol (2005) 0.85
Immunotherapy with concurrent subcutaneous GM-CSF, low-dose IL-2 and IFN-alpha in patients with progressive metastatic renal cell carcinoma. Br J Cancer (2003) 0.85
Management of clinically node negative penile carcinoma: improved survival after the introduction of dynamic sentinel node biopsy. J Urol (2003) 0.84
Comparison of surveillance and retroperitoneal lymph node dissection in Stage I nonseminomatous germ cell tumors. Urology (2002) 0.84
Surveillance can be the standard of care for stage I nonseminomatous testicular tumors and even high risk patients. J Urol (2001) 0.84
Population-based survival of penile cancer patients in Europe and the United States of America: no improvement since 1990. Eur J Cancer (2012) 0.84
Lymphoscintigraphy in oncology: a rediscovered challenge. Eur J Nucl Med (1999) 0.83
Muscle-invasive bladder cancer treated with external beam radiotherapy: pretreatment prognostic factors and the predictive value of cystoscopic re-evaluation during treatment. Radiother Oncol (1998) 0.83
Acquired smooth-muscle hamartoma of the scrotum: a histological simulator? J Cutan Pathol (2004) 0.83
Early onset of renal cancer in a family with Birt-Hogg-Dubé syndrome. Clin Genet (2009) 0.83
Survival after cystectomy for invasive bladder cancer. Eur J Surg Oncol (2010) 0.83
Risk and prognostic significance of metachronous contralateral testicular germ cell tumours. Br J Cancer (2012) 0.82
Hybrid tracers for sentinel node biopsy. Q J Nucl Med Mol Imaging (2014) 0.82
Laparoscopic sentinel lymph node biopsy for prostate cancer: the relevance of locations outside the extended dissection area. Prostate Cancer (2011) 0.81
Randomized Phase II trial assessing estramustine and vinblastine combination chemotherapy vs estramustine alone in patients with progressive hormone-escaped metastatic prostate cancer. Br J Cancer (2004) 0.81
[Information needs of men with prostate cancer and their partners]. Ned Tijdschr Geneeskd (2000) 0.80
Intraoperative sentinel node identification and sampling in clinically node-negative renal cell carcinoma: initial experience in 20 patients. World J Urol (2010) 0.80
Radiofrequency ablation of kidney tumours in patients with a solitary kidney. Clin Radiol (2010) 0.80
The management and prevention of premalignant penile lesions. Scand J Urol Nephrol Suppl (2000) 0.80
Health-related quality of life and psychosocial factors in patients with prostate cancer scheduled for radical prostatectomy or external radiation therapy. BJU Int (2003) 0.79
Functional and histological damage in the mouse bladder after photodynamic therapy. Br J Cancer (1992) 0.79
Sexuality preserving cystectomy and neobladder (SPCN): functional results of a neobladder anastomosed to the prostate. Eur Urol (2003) 0.79
Long-term survival after combined modality treatment in metastatic bladder cancer patients presenting with supra-regional tumor positive lymph nodes only. Eur J Surg Oncol (2008) 0.79
Outcome of treatment of bladder cancer: a comparison between low-volume hospitals and an oncology centre. World J Urol (2010) 0.78
A feasibility study of accelerated fractionation in radiotherapy of carcinoma of the urinary bladder. Int J Radiat Oncol Biol Phys (1997) 0.78
No evidence of benefit from class-II compression stockings in the prevention of lower-limb lymphedema after inguinal lymph node dissection: results of a randomized controlled trial. Lymphology (2013) 0.77
Recurrent priapism as a side effect of zuclopenthixol decanoate. Int Clin Psychopharmacol (1995) 0.77
Serum hemoglobin levels predict response to strontium-89 and rhenium-186-HEDP radionuclide treatment for painful osseous metastases in prostate cancer. Urol Int (2006) 0.77
Short-term outcome after cystectomy: comparison of two different perioperative protocols. Urol Int (2012) 0.77
Port site metastasis after laparoscopic nephro-ureterectomy for transitional cell carcinoma. Eur Urol (2004) 0.76
Re: does partial cystectomy compromise oncologic outcomes for patients with bladder cancer compared to radical cystectomy? A matched case-control analysis. J Urol (2012) 0.76
Penile lymphoscintigraphy for sentinel node identification. Eur J Nucl Med (2001) 0.76
Lymphatic drainage in prostate carcinoma assessed by lymphoscintigraphy and SPECT/CT: its importance for the sentinel node procedure. Rev Esp Med Nucl Imagen Mol (2011) 0.75
Effects of estrogens only on the prostates of aging men. J Urol (1996) 0.75
[Guideline 'Renal cell carcinoma']. Ned Tijdschr Geneeskd (2008) 0.75